Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Practical guide to bone health in the spectrum of advanced prostate cancer.

Butoescu V, Tombal B.

Can J Urol. 2014 Apr;21(2 Supp 1):84-92. Review.

3.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Review.

4.

Bone health and prostate cancer.

Saylor PJ, Smith MR.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. doi: 10.1038/pcan.2009.50. Review.

5.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

6.

Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

Saylor PJ, Michaelson MD.

Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433.

7.

Managing bone metastases and reducing skeletal related events in prostate cancer.

Gartrell BA, Saad F.

Nat Rev Clin Oncol. 2014 Jun;11(6):335-45. doi: 10.1038/nrclinonc.2014.70. Review. Erratum in: Nat Rev Clin Oncol. 2015 Jan;12(1). doi:10.1038/nrclinonc.2014.70.

PMID:
24821212
8.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
9.
10.

Bone health in men with prostate cancer: diagnostic and therapeutic considerations.

Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.

Can J Urol. 2005 Jun;12 Suppl 2:9-15. Review.

PMID:
16018826
11.

Bone-targeted agents: preventing skeletal complications in prostate cancer.

Morgans AK, Smith MR.

Urol Clin North Am. 2012 Nov;39(4):533-46. doi: 10.1016/j.ucl.2012.07.009. Review.

12.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
13.

Bone loss in prostate cancer: evaluation, treatment and prevention.

Saad F.

Can J Urol. 2005 Feb;12 Suppl 1:71-6; discussion 99-100. Review.

PMID:
15780171
14.

Management of bone loss in men with prostate cancer.

Higano CS.

J Urol. 2003 Dec;170(6 Pt 2):S59-63; discussion S64. Review.

PMID:
14610412
15.

Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.

Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S.

Scand J Urol. 2014 Aug;48(4):350-5. doi: 10.3109/21681805.2014.884160.

PMID:
24548220
16.

Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.

Saad F, Abrahamsson PA, Miller K.

BJU Int. 2009 Dec;104(11):1573-9. doi: 10.1111/j.1464-410X.2009.08952.x. Review.

17.

Bone metastases and bone loss medical treatment in prostate cancer patients.

Safriadi F.

Acta Med Indones. 2013 Jan;45(1):76-80. Review.

18.

Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.

Saad F, McKiernan J, Eastham J.

Urol Oncol. 2006 Jan-Feb;24(1):4-12. Review.

PMID:
16414486
19.

[Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].

Todenhöfer T, Schwentner C, Schilling D, Gakis G, Stenzl A.

Urologe A. 2011 Sep;50(9):1055-63. doi: 10.1007/s00120-011-2623-6. Review. German. Erratum in: Urologe A. 2011 Oct;50(10):1322.

PMID:
21744161
20.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Review. German.

PMID:
22875632
Items per page

Supplemental Content

Support Center